News Archive
An international team of researchers has discovered that respiratory syncytial virus (RSV), a common cold virus causing bronchiolitis in children, can act as a 'hit and hide' virus. It was thought that the virus could only survive in the body for a few days, but these new results show that the virus can survive for many months or years, perhaps causing long-term effects on health, such as damage to the lungs.
An international study led by researchers from IMIM (Hospital del Mar Medical Research Institute) published in the journal Nature Communications has revealed that the intensity or efficiency of the activation of a protein called Notch, which is involved in the different phases of embryonic development, determines the fate of cells, i.e. if cells will form the aorta artery or blood (hematopoietic) stem cells. For artery cells, many Notch molecules need to be activated, whereas for hematopoietic cells many fewer are needed.
The parasite Trypanosoma cruzi (or T. cruzi), which causes Chagas' disease, will go to great lengths to evade death once it has infected human host cells, researchers have discovered. In a study published in the November 17 online issue of Science Signaling, the researchers describe how a protein called parasite-derived neurotrophic factor (PDNF) prolongs the life of the T. cruzi parasite by activating anti-apoptotic (or anti-cell-death) molecules in the host cell. These protective mechanisms help to explain how host cells continue to survive despite being exploited by T. cruzi parasites.
Reuters reports that Health and Human Services data show the business community is a big winner as a result of the measure's early retiree program. But The Fiscal Times notes that some "corporate giants" are at odds with the overhaul.
ValueRich, Inc. announced today that the company has commenced litigation against China Pharmaceuticals, a publicly traded company under the symbol for breach of contract and other related claims. ValueRich alleges ownership of 20% of the outstanding shares of China Pharmaceuticals "pursuant to a May 2009 Consulting Agreement between ValueRich and Xian Pharmaceuticals, Ltd, the Chinese-based operating company for China Pharmaceuticals."
› Verified 1 days ago